U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N16O12
Molecular Weight 1209.4006
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEUPROLIDE

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6

InChI

InChIKey=GFIJNRVAKGFPGQ-LIJARHBVSA-N
InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1

HIDE SMILES / InChI

Molecular Formula C59H84N16O12
Molecular Weight 1209.4006
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/ppa/leuprolide.html | http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020011s040lbl.pdf | http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf

Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. It acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. Leuprolide acetate used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, uterine leiomyomata (fibroids), endometriosis and precocious puberty.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LUPRON

Approved Use

LEUPROLIDE ACETATE INJECTION is indicated in the palliative treatment of advanced prostatic cancer.

Launch Date

1985
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Primary
LUPRON DEPOT

Approved Use

Endometriosis LUPRON DEPOT 3.75 mg is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT monthly with norethindrone acetate 5 mg daily is also indicated for initial management of endometriosis and for management of recurrence of symptoms. (Refer also to norethindrone acetate prescribing information for WARNINGS, PRECAUTIONS, CONTRAINDICATIONS and ADVERSE REACTIONS associated with norethindrone acetate). Duration of initial treatment or retreatment should be limited to 6 months. Uterine Leiomyomata (Fibroids) LUPRON DEPOT 3.75 mg concomitantly with iron therapy is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. (See Table 1.) LUPRON may be added if the response to iron alone is considered inadequate. Recommended duration of therapy with LUPRON DEPOT 3.75 mg is up to three months. Experience with LUPRON DEPOT in females has been limited to women 18 years of age and older.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
32.48 ng/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
426.2 ng × h/mL
11.25 mg single, subcutaneous
dose: 11.25 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
54%
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEUPROLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Other AEs: Asthenia, General body pain...
Other AEs:
Asthenia (6 patients)
General body pain (16 patients)
Headache (5 patients)
Injection site reaction (4 patients)
Hot flashes (23 patients)
Gastrointestinal disorder (NOS) (5 patients)
Dehydration (4 patients)
Edema (4 patients)
Disorder joint (8 patients)
Myalgia (4 patients)
Vertigo (3 patients)
Neuromuscular disorders (3 patients)
Paresthesia (4 patients)
Skin reaction (6 patients)
Urinary tract disorder NOS (5 patients)
Sources:
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Other AEs: General body pain, Hot flashes...
Other AEs:
General body pain (13 patients)
Hot flashes (32 patients)
Gastrointestinal disorder (NOS) (8 patients)
Edema (8 patients)
Libido decreased (3 patients)
Disorder urinary tract (7 patients)
Impotence (3 patients)
Atrophy testicular (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
General body pain 16 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Hot flashes 23 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Neuromuscular disorders 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Vertigo 3 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Dehydration 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Edema 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Injection site reaction 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Myalgia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Paresthesia 4 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Gastrointestinal disorder (NOS) 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Headache 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Urinary tract disorder NOS 5 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Asthenia 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Skin reaction 6 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
Disorder joint 8 patients
30 mg 1 times / month multiple, subcutaneous
Highest studied dose
Dose: 30 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 30 mg, 1 times / month
Sources:
unhealthy, adult
General body pain 13 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Atrophy testicular 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Impotence 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Libido decreased 3 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Hot flashes 32 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Disorder urinary tract 7 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Edema 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
Gastrointestinal disorder (NOS) 8 patients
7.5 mg 1 times / month multiple, subcutaneous
Recommended
Dose: 7.5 mg, 1 times / month
Route: subcutaneous
Route: multiple
Dose: 7.5 mg, 1 times / month
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.
1991 Sep-Oct
Angina and myocardial infarction with use of leuprolide acetate.
1994 Jul
[Effects of androgen regulation system on bladder carcinogenesis in male mice].
1995 Nov
"Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri.
1996 Jul
Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
1997 Oct
Steroidal 'add-back' therapy in patients treated with GnRH agonists.
1998
Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy.
1998 Mar 15
Lupron-induced mania.
1999 Jan 15
Pituitary haemorrhage after leuprolide therapy for prostatic cancer, clinically imitating acute subarachnoidal haemorrhage.
2002
Leuprolide-induced myopathy.
2002 Oct
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
2002 Sep
Pituitary apoplexy after leuprolide injection for ovum donation.
2003 Jan
Testicular germ cell tumors exhibit evidence of hormone dependence.
2006 Jan 1
A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
2009 Jun
Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study.
2010 Dec
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.
2011 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Dosing: Adult Prostate cancer, advanced: Note: Treatment is usually continued after development of metastatic (castration-resistant) disease. IM: Lupron Depot 7.5 mg (monthly): 7.5 mg every month or Lupron Depot 22.5 mg (3 month): 22.5 mg every 12 weeks or Lupron Depot 30 mg (4 month): 30 mg every 16 weeks or Lupron Depot 45 mg (6 month): 45 mg every 24 weeks SubQ: Eligard: 7.5 mg monthly or 22.5 mg every 3 months or 30 mg every 4 months or 45 mg every 6 months Leuprolide acetate 5 mg/mL solution: 1 mg daily Endometriosis: IM: Initial therapy may be with leuprolide alone or in combination with norethindrone; if re-treatment for an additional 6 months is necessary, concomitant norethindrone should be used. Re-treatment is not recommended for longer than one additional 6-month course. Lupron Depot: 3.75 mg every month for up to 6 months or Lupron Depot-3 month: 11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment) Uterine leiomyomata (fibroids): IM (in combination with iron): Lupron Depot: 3.75 mg every month for up to 3 months or Lupron Depot-3 month: 11.25 mg as a single injection Breast cancer, premenopausal ovarian supression (off-label use): IM: Lupron Depot: 3.75 mg every 28 days for up to 24 months (Boccardo 1999) or Lupron Depot-3 month: 11.25 mg every 3 months for up to 24 months (Boccardo 1999; Schmid 2007) Treatment of paraphilia/hypersexuality (off-label use; Guay 2009; Reilly 2000): Males: IM: Note: May cause an initial increase in androgen concentrations which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1 to 2 months (Guay 2009). Avoid use in patients with osteoporosis or active pituitary pathology. SubQ: Test dose: 1 mg (observe for hypersensitivity) Depot IM: 3.75 to 7.5 mg monthly Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males): IM: Lupron Depot-Ped (monthly): ≤25 kg: 7.5 mg every month >25 to 37.5 kg: 11.25 mg every month >37.5 kg: 15 mg every month Titrate dose upward in increments of 3.75 mg every 4 weeks if down-regulation is not achieved. Lupron Depot-Ped (3 month): 11.25 mg or 30 mg every 12 weeks SubQ (leuprolide acetate 5 mg/mL solution): Initial: 50 mcg/kg/day; titrate dose upward by 10 mcg/kg/day if down-regulation is not achieved. Note: Higher mg/kg doses may be required in younger children.
Route of Administration: Other
In primary cell cultures from human prostate carcinoma leuprolide (from 5-20 ng/mL) showed a significant reduction in cell growth rate and an increase in DNA-fragmented cell number.
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:29:46 GMT 2025
Edited
by admin
on Wed Apr 02 08:29:46 GMT 2025
Record UNII
EFY6W0M8TG
Record Status FAILED
Record Version
  • Download
Name Type Language
LEUPROLIDE
HSDB   MI   VANDF  
Common Name English
LEUPRORELIN
EP   INN   MART.   WHO-DD  
INN  
Preferred Name English
LEUPRORELIN SLOW RELEASE
Common Name English
leuprorelin [INN]
Common Name English
LEUPROLIDE [HSDB]
Common Name English
TAP-144 FREE BASE
Code English
Leuprorelin [WHO-DD]
Common Name English
LEUPORELIN
Common Name English
NSC-377526
Code English
LEUPROLIDE [MI]
Common Name English
LEUPROLIDE [VANDF]
Common Name English
CKD-841
Code English
ABBOTT-43818 FREE BASE
Code English
(-)-LEUPROLIDE
Common Name English
LEUPRORELIN [MART.]
Common Name English
LEUPRORELIN [EP MONOGRAPH]
Common Name English
5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TRYOSYL-D-LEUCYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE
Common Name English
PGLU-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHC2H5
Common Name English
Classification Tree Code System Code
WHO-ATC L02AE51
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
NDF-RT N0000175654
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
NDF-RT N0000009332
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
WHO-VATC QL02AE02
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
NDF-RT N0000175655
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
NCI_THESAURUS C1910
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
WHO-ATC L02AE02
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
LIVERTOX NBK548676
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
Code System Code Type Description
INN
5025
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
WIKIPEDIA
Leuprorelin
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
EVMPD
SUB08449MIG
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
DAILYMED
EFY6W0M8TG
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
NCI_THESAURUS
C62042
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
RXCUI
42375
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m6779
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY Merck Index
FDA UNII
EFY6W0M8TG
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
DRUG BANK
DB00007
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
CAS
53714-56-0
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
SMS_ID
100000088225
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
IUPHAR
1175
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
DRUG CENTRAL
1559
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
EPA CompTox
DTXSID50872411
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
PUBCHEM
657181
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201199
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
NSC
377526
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
CHEBI
6427
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
HSDB
6518
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
MESH
D016729
Created by admin on Wed Apr 02 08:29:46 GMT 2025 , Edited by admin on Wed Apr 02 08:29:46 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC Males
PHARMACOKINETIC